Schedule 13G Filing for Tenax Therapeutics, Inc.

The filing is a Schedule 13G submitted by multiple reporting persons, including Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Raymond Debbane. The filing discloses their beneficial ownership of common stock in Tenax Therapeutics, Inc. As of October 2, 2025, Invus Public Equities directly held 366,143 shares, and Avicenna Fund directly held 60,998 shares. The filing also includes certifications that the securities were not acquired for the purpose of influencing the control of the issuer. The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934.